Trials / Completed
CompletedNCT01236014
Indirect Comparison Between Eltrombopag & Romiplostim
Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An indirect comparison to compare the efficacy of eltrombopag versus romiplostim
Detailed description
An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eltrombopag | Eltrombopag \& standard of care |
| DRUG | Romiplostim | Romiplostim \& standard of care |
| DRUG | Placebo | Placebo \& standard of care |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2010-11-08
- Last updated
- 2017-06-07
Source: ClinicalTrials.gov record NCT01236014. Inclusion in this directory is not an endorsement.